Zika virus (ZIKV) is responsible for a recent global epidemic that has been associated with congenital brain malformations in fetuses and with Guillain-Barr e syndrome in adults. Within the last 2 years, a major effort has been made to develop murine models to study the mechanism of viral transmission, pathogenesis and the host immune response. Here, we discuss the findings from these models regarding the role that the innate and adaptive immune responses have in controlling ZIKV infection and pathogenesis. Additionally, we examine how innate and adaptive immune responses influence sexual and vertical transmission of ZIKV infection as well as how these responses can influence the ability of ZIKV to cross the placenta and to induce damage in the developing brain.
Introduction
Zika virus (ZIKV) is a flavivirus, first discovered in Uganda in 1947 in a sentinel monkey, which probably contracted the virus via its primary vector, an Aedes mosquito. Historically, human cases were rare with symptoms including mild fever, rash, myalgia and conjunctivitis. 1 However, recent outbreaks in French Polynesia in 2013/ 14 2 and in South America in 2015/16 3 showed an association between ZIKV infection and severe clinical outcomes including Guillain-Barr e syndrome (GBS) in adults 4 and microencephaly and congenital pathologies in fetuses and newborns. 5 The congenital defects were associated with the ability of ZIKV to be transmitted vertically across the placental barrier. 6 Additionally, ZIKV can be transmitted human-to-human sexually from males to females. 7 Recent work has focused on the development of smallanimal models to better understand ZIKV pathogenesis and the role of the immune response elicited during infection in these processes.
Zika virus and the innate immune response
Developing useful murine models of ZIKV infection has been difficult. Early attempts required significant mouse adaptation through serial viral passaging in brain tissue to consistently observe disease. 8 Even using ZIKV isolates from recent outbreaks demonstrated no obvious signs of disease and little to no detectable virus in tissues in wildtype (WT) strains of mice (C57BL/6, BALB/c or CD-1) following peripheral inoculation (Table 1 , part a) suggesting that virus replication is effectively controlled in these animals.
Studies analysing the type I interferon (IFN) responses in human and mouse cells identified a key difference between these species in their ability to control virus infection. In human cells, the virus NS5 protein antagonizes IFN signalling by promoting proteasomal degradation of the human signal transducer and activator of transcription 2 (STAT2) protein. 9, 10 STAT2 is a transcription factor that mediates signalling through the IFN-a/b receptor (IFNAR), leading to the production of IFN-stimulated genes. 11 Hence, ZIKV NS5 limits the type I IFN response during human infection. In contrast, ZIKV NS5 does not inhibit mouse STAT2, allowing for an efficient and effective type I IFN response that controls virus replication. 9 Mice deficient in STAT2 are susceptible to ZIKV infection, 12 as are mice deficient in the IFNAR1 gene (Ifnar1 À/À , A129). These mice develop a rapid wasting disease within 5-8 days and have high viral burdens in [14] [15] [16] This was also observed when IFNAR1 was specifically knocked out in myeloid cells, suggesting that these cells are critical for protection. 17 The molecules necessary to mediate the type I IFN response to ZIKV infection are not as well defined, as deficiency in Mavs, the signalling molecule for RIG-I-like receptors resulted in only a shortterm viraemia, 16 whereas deficiencies in Irf3 or the threedimensional mutation in Unc93b1, which results in deficient endosomal Toll-like receptor responses, had no effect on ZIKV infection. 14, 16 Hence, neither cytoplasmic RIG-I-like receptors nor endosomal Toll-like receptors appear to be essential for protection against ZIKV, suggesting that other sensors of virus infection play a role in mediating the type I IFN response to ZIKV.
Partial disruption of the type I IFN response, to more effectively mimic the antagonism of the type I IFN response found in humans, has been achieved by treating mice with anti-IFNAR antibodies. Treatment of WT mice with a single, large bolus of anti-IFNAR1 blocking antibody (MAR1-53A) does not result in clinical signs such as wasting disease, but can result in detectable virus in peripheral tissues. 14, 18, 19 Furthermore, the concentration of blocking antibody used can influence tissue-specific viral load 14 and result in disease if repeatedly administered. 20 In the future, it may be possible to use this approach as a model of ZIKV-associated GBS because ZIKV infection of Ifnar1 À/À mice can result in peripheral neuron infection and apoptosis 21, 22 ( Figure 1c ).
Adaptive immune response to ZIKV
Although the innate immune response is clearly necessary for controlling viral replication and preventing disease, the adaptive T-cell and B-cell responses also contribute to protection. Several studies, including work from our laboratory, have demonstrated a short-lived, but strong T-cell response around 7 days post infection in ZIKV-infected WT mice. 
Combined influence of innate and adaptive immune responses
Combined deficiencies in components of the innate and adaptive immune response have shown that both arms of the immune system influence ZIKV pathogenesis ( Table 1 , part d). AG129 mice, which lack both IFN type I (a/b) and type II (c), develop disease in an age-dependent manner with younger mice being more susceptible. 13, 15 These mice have similar infection kinetics to A129 mice but with exaggerated disease signs. Depletion or deficiency of T cells in IFN-antagonized mice results in high ZIKV titres and associated disease, demonstrating that the adaptive immune response is critical to controlling infection, when the type I IFN response is suboptimal. 16, 17 Furthermore, adoptive transfer of ZIKV-specific CD8 T cells also prevents disease in Ifnar1 À/À mice, suggesting that a vaccination strategy could be effective at preventing disease, even in the absence of strong IFN responses 17, 23, 25 (Table 1 , part d). In addition to the cellular adaptive response, there is some evidence from mouse models implicating the humoral response in preventing ZIKV-associated disease. Although B cells are not activated during ZIKV infection in WT animals, 16 a strong neutralizing antibody response is correlated with recovery from ZIKV infection in highly susceptible Ifnar À/À mice. 26 Additionally, monoclonal antibodies as well as antibodies derived from convalescent patient serum can inhibit disease in ZIKV-susceptible mice. [27] [28] [29] [30] These antibodies target the envelope (E) glycoprotein, which is required for flavivirus entry into the cell. 31 Multiple candidate ZIKV vaccine platforms are currently being developed to prevent human disease. [32] [33] [34] So far, all effective candidates have demonstrated induction of a potent sterilizing neutralizing antibody titre and a robust T-cell response, further demonstrating the importance of the adoptive immune response to controlling ZIKV infection.
Influence of immune responses on sexual transmission
Although ZIKV is primarily transmitted to humans by the bite of a mosquito, human-to-human transmission can be observed sexually, from infected males to females, 7 and vertically, from a pregnant woman to her fetus. 1, 35, 36 Mouse models have shown that both innate and adaptive immune responses influence both sexual and vertical transmission. For example, Ifnar1 À/À male mice or anti-IFNAR1 treatment of WT male mice develop infection in the testes, which is associated with apoptotic cells following ZIKV infection (Fig. 1a, Table 2 , part a). 18, 37, 38 Similar findings were observed in BALB/c mice treated with dexamethasone. 39 These findings, in association with reports of long-lived infectious virus in human male testes, [40] [41] [42] suggest that ZIKV infection could impact male reproductive health (Fig. 1a) . Additionally, several studies have shown sexual transmission of ZIKV from infected immune-compromised males to naive immune-compromised females (Fig. 1b) . 26, 43 Direct animal-to-animal sexual transmission results in infection of reproductive organs in the female (Fig. 1b) . 26 Enhanced infection of female reproductive tissues by intravaginal inoculation has also been shown in several studies in mice with suppressed type I IFN responses (Irf3
and LysM Cre+ Ifnar fl/fl mice). 44, 45 In contrast, WT mice or mice without severe IFN suppression (Mx1, Rag2 
Immune-mediated mechanisms of ZIKV transmission across the placental barrier
Vertical transmission of ZIKV from infected dam to the fetus has also been successfully modelled in mice (Fig. 2,  Table 2 , part b). This includes infection of immune-competent and immune-compromised mice, by intraperitoneal, subcutaneous or intravaginal routes at either early (E4-5-E7) or late (E13-15) stages of fetal development. Virus has been detected in the fetal central nervous system (CNS) by RNA, histological and focus-forming assay with pathology demonstration of fetal growth restriction, as well as cortical thinning and apoptosis of neurons in the fetal brain. The timing of infection during pregnancy may greatly influence this response as younger embryos/ placentas in infected mice are more likely to develop fetal insufficiency rather than develop microcephaly. 46 These models allow investigators to address an important question in terms of the ZIKV pathogenesis, how does ZIKV cross the placental barrier? This barrier is established with in several days of conception 47 and is necessary for maintaining the pregnancy. A critical function of the placenta is to connect the maternal and fetal blood (Fig. 2a,c) . In both humans and mice, this critical interface is maintained and controlled by syncytiotrophoblasts, 47, 48 suggesting that the mouse may be a useful model to study transmission. ZIKV may enter the fetal blood through various mechanisms involving both the maternal and fetal immune systems. Maternal immune cells may become infected and be transported across the syncytiotrophoblast layer into close proximity to the fetal blood supply (Fig. 2c) . Alternatively, syncytiotrophoblasts may be damaged by maternal immune cells through direct or indirect cytotoxic mechanisms leading to breakdown of the placental barrier (Fig. 2c) . It is also possible that ZIKV may be trafficked across the placental barrier via immunoglobulin-mediated transcytosis, as has been suggested for other placenta-invasive viruses (Fig. 2c) . 49 This mechanism could be facilitated by dengue-specific cross-reactive antibody, which has been shown to enhance ZIKV infection. 50 On the fetal side of the barrier, resident macrophage Hofbauer cells are known to be activated by ZIKV infection. 51 These cells may cross the fetal endothelium and become infected before returning to the fetal blood or may damage the fetal endothelium in response to infection (Fig. 2c) . Although any of these mechanisms may contribute to ZIKV crossing the placenta, caution must be applied when drawing conclusions from murine models. Mice are haemotrichorial in that three layers of syncytiotrophoblasts separate maternal from fetal blood whereas humans are haemochorial with a single layer of syncytiotrophoblasts. Hence, findings from murine models should be verified in other haemochorial systems such as guinea pigs. 52 
Effect of fetal CNS inflammation on brain development and pathogenesis
Important questions remain regarding ZIKV infection and vertical transmission such as how the virus mediates damage to the developing brain and the role of the immune response in mediating this damage. Direct intravaginal inoculation of the dam or intracerebral injection of ZIKV into fetuses at late stages of embryonic development or early points post birth have shown clear damage to the developing brain, including cortical thinning, decreased brain size, decreased neuroprogenitor cell numbers and gliosis (Fig. 2, Table 2 ). However, the role of the immune response in mediating this damage is only starting to be examined. Exposure to virus in utero can elicit a strong local immune response within the fetus, which is mediated by pro-inflammatory cytokines such as TNF, IL-1b, IFN-b and IFN-c. 53 Such exposure can cause both behavioural and CNS structural pathology in offspring, which is correlated with changes in developmental gene expression within the CNS. 54 Experiments using poly(I:C) injected into pregnant mice to mimic viral infection have demonstrated that the cytokine profile induced in the fetal CNS is dependent on the gestational age when exposed to the stimulus. 55 Fetuses exposed at earlier embryonic time-points express higher levels of pro-inflammatory cytokines in their brain, which correlates with increased CNS pathology and worsened behavioural outcomes. Hence, immune responses generated in the developing fetal brain caused by early exposure to ZIKV may account for the more severe phenotypic outcomes seen in these models of ZIKV vertical transmission, such as fetal abortion/resorption, ( Table 2, part  b) . 19, 44, 56, 57 In contrast, CD8 T cells may play a role in clearing virus from the brain as they are the predominant infiltrate in a model of ZIKV infection in neonatal immunocompetent mice. 58 Fetal mice exposed to ZIKV later in development generally present with neurodevelopmental pathologies such as cortical thinning, neuronal death, reduced neural progenitor proliferation, white matter damage and gliosis (Table 2 , part c). One study found that neonatal mice injected intracerebrally with ZIKV have increased levels of Tnf, Il6, Il1b, Nos2 and Ccxcl1 mRNA in their brains at the peak of viral replication, which are associated with increased incidence of seizure. 59 Hence, virus-associated neuroinflammation may contribute to these neuropathologies. Similar behavioural abnormalities are observed when neonatal mice are directly injected intracerebrally with TNF-a, indicating impaired CNS development. 60 Furthermore, IL-6 when applied to neural progenitor cells in vitro decreases their differentiation into mature neurons and increases programmed cell death, suggesting that pro-inflammatory cytokines may be detrimental to neurodevelopment. 61, 62 Interleukin-1b and TNF have similar effects when applied to rat embryonic primary cortical neurons. 63 In this way, virus-associated pro-inflammatory cytokines produced in the CNS during development could, in part, account for the reduced brain volumes and impaired cortical patterning observed in ZIKV-associated cases of microcephaly. 64 In related studies, intracerebral injection of TNF and IL1b into neonatal rat brain results in increased astrogliosis and microgliosis, 65 suggesting that these cytokines could contribute to the reactive gliosis observed in models of ZIKV infection in developing brains (Table 2 , part c). Likewise, these cytokines, regardless of whether they are directly injected or are induced by hypoxic injury in the neonatal brain, have been shown to induce oligodendrocyte death and hypomyelination of axons. 65, 66 Hence, pro-inflammatory cytokines may also contribute to the white-matter injury and hypomyelination associated with ZIKV infection in the developing brain (Table 2 , part c). 67, 68 Furthermore, microglia have been associated with synaptic pruning during development, 69 which is a necessary process for cellular patterning and function. Stimulation of developmentally immature microglia with poly(I:C) can shift these cells toward a more mature, reactive phenotype. 70 Hence, ZIKV infection may predispose the developing brain to abnormal synaptic pruning, as is the case with Fragile-X syndrome. 71 Collectively these data suggest that activation of glial responses during CNS development will probably have a negative outcome during fetal development.
Conclusions and future directions
The ability to use a large variety of knockout mice and antibody treatments have provided the tools to gain a basic understanding of the key innate and adaptive immune responses that are essential for controlling ZIKV infection and preventing both pathogenesis and transmission. As one of the most harrowing outcomes of ZIKV infection is microcephaly, the use of vertical transmission models and CNS developmental models to dissect the mechanisms by which ZIKV induces damage to the developing CNS is essential. Therapeutic studies have indicated a potential for improving CNS developmental outcomes during fetal viral infection. For example, administration of anti-TNF antibodies reduced the incidence of seizures in neonatal mice injected intracerebrally with ZIKV. 59 Hence, measures taken to minimize the pro-inflammatory response in the CNS of fetuses with ZIKV infection may improve developmental outcomes. However, further studies are needed to determine the efficacy of any such intervention and should ensure that the innate immune viral clearance mechanisms within the CNS cells are not impaired.
